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Abstract
Background: Human melanoma frequently colonizes bone marrow (BM) since its earliest stage of systemic
dissemination, prior to clinical metastasis occurrence. However, how melanoma cell adhesion and proliferation
mechanisms are regulated within bone marrow stromal cell (BMSC) microenvironment remain unclear. Consistent
with the prometastatic role of inflammatory and angiogenic factors, several studies have reported elevated levels
of cyclooxygenase-2 (COX-2) in melanoma although its pathogenic role in bone marrow melanoma metastasis is
unknown.
Methods: Herein we analyzed the effect of cyclooxygenase-2 (COX-2) inhibitor celecoxib in a model of generalized
BM dissemination of left cardiac ventricle-injected B16 melanoma (B16M) cells into healthy and bacterial endotoxin
lipopolysaccharide (LPS)-pretreated mice to induce inflammation. In addition, B16M and human A375 melanoma
(A375M) cells were exposed to conditioned media from basal and LPS-treated primary cultured murine and human
BMSCs, and the contribution of COX-2 to the adhesion and proliferation of melanoma cells was also studied.
Results: Mice given one single intravenous injection of LPS 6 hour prior to cancer cells significantly increased
B16M metastasis in BM compared to untreated mice; however, administration of oral celecoxib reduced BM
metastasis incidence and volume in healthy mice, and almost completely abrogated LPS-dependent melanoma
metastases. In vitro, untreated and LPS-treated murine and human BMSC-conditioned medium (CM) increased
VCAM-1-dependent BMSC adherence and proliferation of B16M and A375M cells, respectively, as compared to
basal medium-treated melanoma cells. Addition of celecoxib to both B16M and A375M cells abolished adhesion
and proliferation increments induced by BMSC-CM. TNFa and VEGF secretion increased in the supernatant of LPS-
treated BMSCs; however, anti-VEGF neutralizing antibodies added to B16M and A375M cells prior to LPS-treated
BMSC-CM resulted in a complete abrogation of both adhesion- and proliferation-stimulating effect of BMSC on
melanoma cells. Conversely, recombinant VEGF increased adherence to BMSC and proliferation of both B16M and
A375M cells, compared to basal medium-treated cells, while addition of celecoxib neutralized VEGF effects on
melanoma. Recombinant TNFa induced B16M production of VEGF via COX-2-dependent mechanism. Moreover,
exogenous PGE2 also increased B16M cell adhesion to immobilized recombinant VCAM-1.
Conclusions: We demonstrate the contribution of VEGF-induced tumor COX-2 to the regulation of adhesion- and
proliferation-stimulating effects of TNFa, from endotoxin-activated bone marrow stromal cells, on VLA-4-expressing
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reproduction in any medium, provided the original work is properly cited.melanoma cells. These data suggest COX-2 neutralization as a potential anti-metastatic therapy in melanoma
patients at high risk of systemic and bone dissemination due to intercurrent infectious and inflammatory diseases.
Introduction
A significant proportion of cancer patients with no clini-
cal evidence of systemic dissemination will develop
recurrent disease after primary tumor therapy because
they already had a subclinical systemic spread of the dis-
ease [1]. Bone marrow (BM) is a common site of occult
trafficking, infiltration and growth of blood-borne cancer
cells, and their metastases are a major cause of morbid-
ity [2]. Not surprisingly, circulating cancer cells infiltrate
BM tissue and interact with hematopoietic microenvir-
onment at early stages of progression for most of cancer
types [3]. Subsequent invasion and growth of metastatic
cells at bony sites appear to be facilitated by TGFb [4]
and hematopoietic growth factors [5,6], tumor-asso-
ciated angiogenesis [7,8] and bone remodeling [9]. Thus,
the understanding of complex interactions between can-
cer and bone cells/bone marrow stromal cells leading to
these prometastatic events is critical for the design of an
organ-specific therapy of bone metastasis.
The BM colonization of metastatic tumors, both of
epithelial and non-epithelial origins, is promoted by
inflammation [6,10]. Proinflammatory cytokines released
by cancer cells [11] and tumor-activated BM stromal
cells [12] increase cancer cell adhesion to bone cells
[13] and bone resorption [14,15]. In addition, PGE2
induces VEGF [16] and osteoclast formation [17] in pre-
clinical models of bone-metastasizing carcinomas, sug-
gesting that inflammation can lead to tumor-associated
angiogenesis and osteolysis with the involvement of
cyclooxygenase-2 (COX-2)-dependent mechanism. Inter-
estingly, COX-2 gene is constitutively overexpressed by
most of human epithelium-derived malignant tumors
and plays a role in their growth [18-20] and metastases
[21]. Human melanoma, a non-epithelial tumor charac-
terized by a marked inflammatory stromal response and
osteolytic metastases, also overexpresses COX-2 gene
[22], which may be correlated with the development and
progression of disease [23]. Moreover, as shown by
immunohistochemistry, COX-2 expression in primary
melanomas is restricted to melanoma cells and signifi-
cant correlation between immunohistochemical staining,
tumor thickness and disease-specific survival has been
reported [24], suggesting that COX-2 is a prognostic
marker and a potential therapeutic target, although its
role in the complex pathogenic process of bone metasta-
sis is unclear [3].
In the present study, we analyzed the effect of a selec-
tive COX-2 inhibitor celecoxib –a 1,5 diarylpyrazole
with >300-fold selectivity for COX-2 versus COX-1
[25]– in a model of generalized BM dissemination of
left cardiac ventricle-injected B16 melanoma (B16M)
cells [26] into healthy and LPS-pretreated mice, to
mimic the prometastatic effects of systemic inflamma-
tion [26-29]. Next, we studied the role of COX-2 in the
regulation of murine B16 and human A375 melanoma
cell adhesion and proliferation in response to primary
cultured murine and human BM stromal cell (BMSC)-
conditioned media (CM) in vitro. Furthermore, the spe-
cific effect of exogenous and endogenous BMSC-derived
VEGF as mediator of COX-2-dependent melanoma cell
adhesion and proliferation was also evaluated in vitro.
Our data demonstrate the remarkable contribution of
tumor COX-2 to the regulation of melanoma cell adhe-
sion to BMSCs and proliferation in response to BMSC-
derived VEGF, and suggest anti-metastatic effects of
neutralizing COX-2 in melanoma patients at high risk
of bone dissemination.
Materials and methods
Drugs
SC-58635 (celecoxib) was provided by Richard A. Marks
(Manager, Discovery Res. Adm., GD Searle & Co, Sko-
kie, IL). In addition, Lab Control 1/2 (non-irradiated)
Rodent Chao at 1600 PPM and Mod Cert Rodent w/o
16% celecoxib were also provided by GD Searle & Co,
Skokie, IL.
Animals
Syngeneic C57BL/6J mice (male, 6-8 weeks old) were
obtained from IFFA Credo (L’Arbreole, France). Animal
housing, their care and experimental conditions were
conducted in conformity with institutional guidelines
that are in compliance with the relevant national and
international laws and policies (EEC Council Directive
86/609, OJ L 358. 1, Dec. 12, 1987, and NIH guide for
the care and use of laboratory animals. NIH publication
85-23, 1985).
Culture of Cancer Cells
Murine B16 melanoma (B16M) cells from the B16F10
subline, and human A375 melanoma (A375M) cell lines
were obtained from ATCC (Manassas, VA) and utilized
in the present study. Both cell lines were cultured in
endotoxin-free Dulbecco’s modified Eagle’sm e d i u m
supplemented with 10% FCS and penicillin-streptomy-
cin, all from Sigma-Aldridch (St Louis, MO). Cultures
were maintained and passaged as previously described
[29].
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Ventricle Injection
Mice (10 per experimental group; experiments per-
formed in triplicate) were anesthetized with Nembutal
(50 mg/kg body weight), kept at a warm temperature of
25°C, and the anterior chest wall was shaved and pre-
pared for aseptic surgery by washing with iodine and
70% ethanol. The ribs over the heart were exposed, and
a 30-gauge needle attached to a tuberculin syringe was
inserted through the second intercostal space to the left
of the sternum, into the left ventricle. When blood
entered the tip of the needle, 5 × 10
4 viable cancer cells
in 50 μL HEPES-buffered DMEM were injected. The
needle was withdrawn slowly, and the muscle and skin
were closed with a single suture. Mice received one sin-
gle intravenous injection of 0.5 mg/kg bacterial endo-
toxin lipopolysaccharide (LPS, E. coli, serotype O127:B8)
or vehicle, 6 h before left cardiac ventricle injection of
B16M cells. Then, they were treated with vehicle or cel-
ecoxib until being killed on the 15
th day postinjection.
Celecoxib was supplied daily in the diet at a dose of 500
mg/Kg along all the assays. The following animal groups
(120 mice) were used: (a) Vehicle-treated normal mice
(10 mice × 3 experiments); (b) Celecoxib-treated normal
mice (10 mice × 3 experiments); (c) Vehicle-treated
LPS-injected mice (10 mice × 3 experiments); and (d)
Celecoxib-treated LPS-injected mice (10 mice × 3
experiments).
Bone Marrow Metastasis Quantitation
The skeletal system of each mouse was completely dis-
sected. The number of metastatic nodules was recorded
under a dissecting microscope (magnification, 10 ×) for
each of the following bones: spine (cervical, thoracic,
lumbar, and sacral bones), skull (maxilla, mandible, and
cranium), thorax (sternum, ribs, and scapula), pelvis
(ilium, ischium, and pubis), foreleg (humerus and
radius) and hindleg (tibia and femur). On the basis of
this inspection, each bone was scored as either contain-
ing a metastatic nodule or being free of microscopic
tumor. The percentage of bones positive for metastasis
was calculated for the total number of mice in each
group (metastasis incidence). In addition, metastasis
volume was estimated for each bone segment at the
time of mouse death. To accomplish this, bones were
directly observed under a video-camera zoom (magnifi-
cation, 10 ×), and the highly contrasted images of bone
segments were digitalized. Then, a densitometric pro-
gram was used to discriminate the black tissue (melano-
tic metastases) from normal bone tissue and to calculate
the percentage of the bone image occupied by metas-
tases. The metastasis volume was then obtained for each
bone segment as follows: the number of recorded
metastases per bone segment (maximum of 10) was
multiplied by the average percentage of surface occupied
by metastasis per bone segment (maximum of 100%)
and expressed as a relative percentage with respect to a
previously defined maximum for each individual bone
segment. To avoid subjective influences on the study of
metastases, the recordings were made in a blind fashion.
Paired and multiple bones were considered as single
bone site with the calculated incidence and metastasis
development indices including both or all of the bones,
respectively, within an animal. Finally, metastasis inci-
dence and volume in LPS-treated mice were expressed
as mean increase percentages with respect to control
mice and in the case of celecoxib-treated mice, results
were expressed as metastasis incidence and volume inhi-
bition percentages with respect to either untreated mice
or LPS-treated animals fed with control chow.
Murine and Human BMSC Isolation, Culture and
Characterization
For murine BMSC isolation, femurs and tibias were
removed and perfused with 10 ml DMEM. The BMSC-
rich effluent was transferred into 25 cm
2 culture flasks
and maintained for two days at 37°C in a humidified
atmosphere with 5% CO2. Once murine BMSCs had
spread out on the culture substrate, the culture medium
was exchanged and supplemented with 20% horse
serum and 200 μg/ml endothelial cell growth factor sup-
plement (ECGS, from Sigma-Aldridch, St Louis, MO), as
previously described [30].
For human BMSC isolation, bone marrow aspirates
were obtained from patients undergoing bone marrow
harvest for autologous bone marrow transplantation,
after informed consent. The BM aspirate was immedi-
ately diluted in 1:1 in Hanks’ balanced salt solution
(HBSS) containing 1 Mmol/L EDTA, and passed
through a 40-μm stainless steel filter to remove
loosely attached hematopoietic cells. The filter was
then placed in a 50 ml conical tube and retained stro-
mal elements were resuspended in 5 ml HBSS, fol-
lowed by the addition of 0.1% collagenase
(Worthington Biochem. Co., Lakewood, NC) for 30
min at 37°C. The digested material was filtered
through a nylon gauze and centrifuged at 200 g for 5
min at room temperature. Then, cells were cultured
in 75-cm2 plastic culture flasks in a concentration of
1×1 0
6 cells per ml of medium containing alpha-
minimum essential medium (GIBCO, Life Technolo-
gies, Gaithersburg, MD), 12.5% fetal calf serum (FCS,
GIBCO), 12.5% horse serum (GIBCO), 200 μg/ml
ECGS, 10-3 M, hydrocortisone sodium succinate
(Sigma), 10-2 M beta-mercaptoethanol (Sigma), 10
μg/ml gentamicine and 10 μg/ml penicillin-streptomy-
cin (Sigma). Cultured were maintained in a humid
atmosphere at 37°C and 5% CO2.
Valcárcel et al. Journal of Translational Medicine 2011, 9:142
http://www.translational-medicine.com/content/9/1/142
Page 3 of 14Murine and human BMSCs were characterized on the
7
th or 15
th day of primary culture, respectively. To iden-
tify reticular and endothelial cell phenotypes, BMSCs
were incubated with 10 μg/ml Dil-Ac-LDL (Biomedical
Technologies, Inc., Stoughton, MA) for 6 h and with 1
×1 0
7 FITC-conjugated latex particles/ml (Polysciences,
Warrington, PA) for one additional hour. Under fluores-
cence, light and phase-contrast microscopy, the number
of single and double-labeled BMSCs was recorded in
randomly chosen microscopic fields (n = 20) at a magni-
fication of × 400. LDL endocytotic BMSCs, which did
not take up latex particles (non-phagocytotic), were con-
sidered as endothelial cells, while double-labeled cells
were considered as phagocytotic reticular cells. Other
BMSCs were resuspended, fixed in cold 70% methanol
for 30 min, washed and incubated with anti-human von
Willebrand factor antibody (Serotec Ltd., Oxford, Eng-
land) diluted 1:100 in PBS-1% BSA for 30 min at room
temperature; BMSCs were then washed and incubated
with a FITC-conjugated rabbit anti-mouse IgG anti-
serum (1:10 diluted in PBS-1% BSA) for 30 min at room
temperature. Omission of the primary antibody was
used as control of non-specific binding of the secondary
antibody.
Once BMSCs had been characterized, they were resus-
pended and replated at 1 × 10
6 cells/well/ml in 24-well
plates. Murine and human BMSC conditioned media
(BMSC-CM) were prepared as follows: cultured BMSCs
were incubated for 30 min with basal medium or 1 ng/
ml LPS. Then, cells were washed and incubated with
serum-free medium for additional 6 h and supernatants
were collected, centrifuged at 1,000 g for 10 min, 0.22
μm-filtrated and used undiluted to treat B16M or
A375M cells.
Cancer Cell Adhesion Assay to Primary Cultured BMSCs
Murine and human BMSCs were cultured for 15 days
prior to be used in adhesion assays. B16M and A375M
cells were labeled with 2’,7’-bis-(2-carboxyethyl)-5,6-car-
boxyfluorescein-acetoxymethylester (BCECF-AM) solu-
tion (Molecular Probes, Eugene, OR). Next, 2 × 10
5
cancer cells/well were added to 24-well-plate cultured
BMSCs and 10 min later, wells were washed three times
with fresh medium. The number of adhering cancer
cells was determined using a quantitative method based
on a previously described fluorescence measurement
system [29]. In some experiments, cancer cells were
incubated for 4 h with 6 h-untreated or LPS-treated
murine or human BMSC-CM before their addition to
BM stromal cells. Some murine BMSC-CM were pre-
incubated with 10 μg/ml anti-murine VCAM-1 mono-
clonal antibodies (R&D Systems, Minneapolis, MN) at
37°C for 30 min before their addition to cancer cells.
For celecoxib-treated groups, 1 μg/ml celecoxib was
added to cancer cells 30 min prior to basal medium
(DMEM), BMSC-CMs, 10 ng/ml recombinant murine
or human VEGF (R&D Systems, Minneapolis, MN) or
100 ng/ml PGE2 (R&D Systems, Minneapolis, MN).
Cancer Cell Adhesion Assay to Immobilized Recombinant
VCAM-1
Ninety six-well plates were coated with 2 μg/ml recom-
binant human VCAM-1 (R&D Systems, Minneapolis,
MN) at 4°C overnight. Nonspecific binding sites on plas-
tic were blocked by treating the wells with 100 μl of PBS
containing 0.5% BSA for 2 h at room temperature. In
some experiments, B16M cells were incubated with
either basal medium, or two different concentrations of
PGE2, 10 and 100 ng/ml (Sigma Chemicals, St. Louis,
MO) for 2 h, or with 1 μg/ml celecoxib for 30 min
before addition of 100 ng/ml recombinant mouse VEGF
(R&D Systems, Minneapolis, MN). In other experiments,
A375M cells were preincubated with or without 1 μg/ml
celecoxib for 30 min before addition of basal medium, 6
h-untreated or LPS-treated BMSC-CM, and 10 ng/ml
recombinant human VEGF (R&D Systems, Minneapolis,
MN) for other 4 h. Then, B16M or A375M cells were
BCECF-AM-labeled and after washing, they were added
(5 × 10
4 cells/well) to quadruplicate wells. Then, plates
were incubated for 30 min, in the case of B16M cells, or
for 60 min in the case of A375M cells, at 37°C before
unattached cells were removed by washing three times
with fresh medium. The number of adhering cells was
determined using a quantitative method based on a pre-
viously described fluorescence measurement system [29].
Cancer Cell Proliferation Assay
Murine and human BMSC-conditioned media (BMSC-
CM) were added to 2.5 × 10
3 B16M and A375M cells,
respectively, seeded into each well of a 96-well microtiter
plate, in the presence or not of either 1 μg/ml celecoxib or
1 μg/ml anti-VEGF monoclonal antibody. Control mela-
noma cells were cultured in the presence of basal medium
(DMEM) used in generating BMSC-CM. In some wells, 10
ng/ml recombinant VEGF was added to melanoma cells in
the presence or not of 1 μg/ml celecoxib. After 48 h incu-
bation, B16M and A375M cell proliferation was measured
using sulforhodamine B protein assay, as previously
described [31]. Each proliferation assay was performed in
cuadruplicate and repeated three times.
Measurement of Cytokine Concentration in murine BMSC
supernatants
TNFa and VEGF concentration were measured in
supernatants from primary cultured BMSC using an
ELISA kit based on specific murine TNFa and VEGF
monoclonal antibodies as suggested by the manufactures
(R&D Systems, Minneapolis, MN).
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To study COX-2 expression by cultured B16M, basal
medium-cultured B16M cells were treated or not for 4
h with 10 and 100 ng/ml recombinant murine VEGF.
Then, they were collected in the lysis buffer [300 mM
NaCl, 50 mM HEPES, 8 mM EDTA, 1% NP40, 10% gly-
cerol, 1 mM Na3VO4, 0.1 mM DTT, 10 mM NaF and
protease inhibitor cocktail tablets, as suggested by the
manufacturer (Roche Diagnostics, Mannheim, Ger-
many)]. Same amount of protein from cell lysates were
size-separated on 10% SDS-PAGE gel and transferred
overnight to a nitrocellulose membrane (BioRad,
Laboratories, Hercules, CA). Blots were blocked for 2 h
with 5% non-fat milk and then incubated for 1 h with
rabbit monoclonal antibody against human COX-2
(Oxford Biomedical Research, Rochester Hills, MI)
diluted 1:500 with PBS. Blots were then incubated with
peroxidase conjugate anti-rabbit IgG (Santa Cruz Bio-
technology, Santa Cruz, CA). Bands were visualized
using the Super Signal West Dura Extended Substrate
kit (Pierce, Rockford, IL). Equal protein loading in the
10% SDS-PAGE electrophoresis was confirmed by
immunoblotting for beta-tubulin expression. Bands were
scanned and densitometrically analyzed using the NIH
image analysis program for Macintosh to obtain normal-
ized COX-2/b-tubulin values.
To study VCAM-1 expression by BMSCs, basal med-
ium-cultured cells received or not 1 ng/ml LPS for 6 h.
T h e n ,t h e yw e r ew a s h e dw i t hP B Sa n dd i s r u p t e dw i t h
RIPA buffer (50 mM Tris, 150 mM NaCl, 1% NP-40,
0.5% deoxycholic acid, 0.1% sodium dodecyl sulfate, 2
m ME D T A ,1 0m MN a F ,1 0μg/ml leupeptin, 20 μg/ml
aprotinin, a nd 1 mM phenylmethylsulfonylfluoride).
Proteins from cell lysates were immunoprecipitated with
10 μgg o a ta n t i - m o u s ea g a r o se-conjugated VCAM-1
polyclonal antibody (Santa Cruz Biotechnology, Santa
Cruz, CA) and blots were blocked and incubated with
rat anti-mouse VCAM-1 monoclonal antibody (Serotec
Ltd) diluted 1:500 with 5% milk-PBS. Blots were next
incubated with peroxidase co n j u g a t e dg o a ta n t i - r a tI g G
(Santa Cruz Biotechnology, Santa Cruz, CA). Bands
were visualized using the Super Signal West Dura
Extended Substrate kit (Pierce, Rockford, IL) and were
scanned and densitometrically analyzed using the NIH
image analysis program for Macintosh to obtain normal-
ized VCAM-1/b-tubulin values.
Statistical Analyses
Data were expressed as statistical software for MS win-
dows, release 6.0 (Professional Statistic, Chicago, IL).
Homogeneity of the variance was tested using the
Levene test. If the variances were homogenous, data
were analyzed by using one-way ANOVA test with
Bonferroni’s correction for multiple comparisons when
more than two groups were analyzed.
Results
Inhibition of Melanoma Bone Marrow Metastasis by
Celecoxib
Mice developed a mean number of 35 ± 6 macroscopic
metastases by day 15 after LCV injection of B16M cells.
As previously reported [26], bone was one of the most
f r e q u e n ts i t e so fm e t a s t a s i si nt h i st u m o rm o d e l .T h e
histological examination of bones by day 10 after cancer
cell injection prior to macroscopic development of
metastases, revealed subclinical micrometastases limited
to the hematopoietic tissue of red BM, which indicates
that bone-infiltrating B16M cells specifically colonized
extravascular compartments of BM (Figure 1A and 1B).
Thereafter, macroscopic metastases occurred in the per-
iphery of flat bones and in the metaphysis of long
bones. In addition, metastasis incidence variation among
different bone segments (Figure 1C, D and 1E) made it
possible to define two bone subgroups: 1) Bones with
high metastasis incidence (Table 1), involving the max-
illa, mandible, spine, ribs, ilium, humerus, scapula,
femur, and tibia; and 2) bones with low metastasis inci-
dence (having 50% fewer metastases), comprising the
radius, pubis, ischium, sternum, and cranium.
Mice given 0.5 mg/kg LPS as a single intravenous
injection 6 h prior to B16M cell injection exhibited a
generalized enhancement of bone metastasis, which sig-
nificantly (P < 0.05) raised the number of bony sites
harboring metastases per mouse compared to saline-
treated mice (Figure 2A and 2B). However, this prome-
tastatic effect of endogenous inflammation was also
bone-specific: 1) LPS significantly (all P <0 . 0 5 )
increased the metastasis incidence and volume in the
maxilla, mandible and scapula; 2) metastasis volume, but
not incidence, significantly (all P < 0.05) increased in the
femur, tibia and spine; 3) metastasis incidence, but not
its volume, significantly (all P < 0.05) increased in the
humerus and ilium; and 4) no significant metastasis
increase was observed in ribs.
Other mice received either control chow or chow con-
taining 16% celecoxib since the time of tumor injection.
Application of this treatment schedule to B16M cell
LCV-injected healthy mice significantly (P <0 . 0 1 )
reduced the formation of metastases in several bones.
There was a statistically significant (all P <0 . 0 5 )r e d u c -
tion of metastasis incidence in the spine, pubis, femur,
tibia, humerus, and radius, whereas the decrease of inci-
dence in maxilla, mandible, ilium, ischium, ribs, scapula
and sternum was not significant in comparison to con-
trol mice (Figure 3A). In addition, the metastasis volume
dropped significantly (all P < 0.05) in most of bones
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Figure 1 (Aa n dB ) Bone marrow micrometastases (arrows) surrounded by red hematopoietic tissue in vertebral bodies on the 10
th
day after B16 melanoma cell injection (Scale bars: 250 μm in A and 50 μmi nB ) . (C) Gum pigmentation due to mandible metastasis and
(D) skull of a mouse showing a melanotic nodule (arrows) in flat bones on the 15th day following left cardiac ventricle injection of B16M cells
(Scale bars: 4 mm); (E) Compression of the spinal cord due to metastases of B16M cells to lumbar vertebral bodies (arrows) was observed (Scale
bar: 2 mm).
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tibia and radius (Figure 3B). Therefore, an important
number of metastases in evaluated bones depended on
COX-2-dependent activity under normal physiological
conditions. Conversely, celecoxib-unaffected metastases
also occurred in several bones, indicating that other
COX-2-independent mechanisms also contributed to
metastasis.
In mice receiving celecoxib since the time of LPS
administration, LPS-mediated enhancement of both
metastasis incidence (Figure 3C) and volume (Figure
3D) significantly decreased as compared with LPS-trea-
ted mice. This indicates that of the many endogenous
factors released in response to LPS, those COX-2-
dependent accounted for metastasis-promoting effects of
LPS in some bones. However, the fact that LPS-
mediated metastasis incidence augmentation did not sig-
nificantly (P < 0.01) decrease in maxilla, mandible,
femur and ribs with celecoxib treatment indicates that
other COX-2-independent mechanisms were contribut-
ing to prometastatic effects of LPS in these bones. Cele-
coxib also inhibited LPS-induced metastases in other
organs, as for example liver, lung, adrenals, and kidney.
However, not statistically significant variations of metas-
tasis parameters were observed in heart, testes, brain,
skin, and gastrointestinal tract, as compared to
Table 1 Metastasis development in high metastasis
incidence bones following Injection of murine B16
melanoma cells into the left cardiac ventricle of mice*
Metastasis Average Metastasis
Bones Incidence (%)† Development index
Maxilla 76.1 63.2 ± 4.3
Mandible 77.5 63.2 ± 3.9
Tibia 69.6 51.9 ± 3.5
Femur 74.4 40.6 ± 2.7
Spine 68.4 32.5 ± 2.7
Ribs 72.2 26.5 ± 2.9
Scapula 58.3 35.4 ± 2.0
Humerus 73.5 42.6 ± 3.5
*30 mice from 3 independent experiments (10 mice in each experimental
group) were cervically dislocated on the 15
th day after left cardiac ventricle
injection of 5 × 104 melanoma cells in 0.1 ml HEPES-buffered DMEM. See
“Materials and Methods” section for details.
†Each bone was scored as either containing a metastatic nodule or being free
of microscopic tumor, and the percentage of bones positive for metastases
was calculated for the total number of bones sites.
The number of recorded metastases per bone segment (maximum of 10) was
multiplied by the surface percentage occupied by metastases (maximum of
100) and expressed as a relative percentage with respect to a previously
defined maximum for each individual bone segment. Data represent average
values ± SD (n = 30).
Paired and multiple bones were considered as single organ sites with the
incidence and metastasis development index calculated including both or all
the bones within an animal.
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Figure 2 Effect of LPS on the metastasis incidence (A) and
volume (B) of major bone segments of mice injected in the
LCV with B16M cells. Mice (n = 15) were injected intravenously
with LPS (0.5 mg/kg body weight). Control mice (n = 15) received
the same volume of saline. Six hours later, both mouse groups were
LCV-injected with 5 × 10
4 B16M cells in 0.1 ml HEPES-buffered
DMEM as described in Methods. After 15 days all mice were killed
by cervical dislocation and the incidence and volume of metastasis
were determined using morphometrical procedures. This
experiment was repeated three times. Results are expressed as
mean increase percentages with respect to metastasis incidence
and volume in control mice.
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Figure 3 Inhibitory effect of celecoxib administration on BM
metastasis in untreated (A and B) and LPS-treated mice (C and
D). Mice received either saline or LPS (20 mice per group) 6 h prior
to B16M cell injection as above. Ten mice of each group received
control chow and the other ten mice received chow containing
16% celecoxib. Treatment was initiated at the time of tumor
injection. Mouse killing on day 15 and metastasis assessment was
done as above. The experiment was repeated three times. Results
are expressed as average metastasis incidence (A and C) and
volume (B and D) inhibition percentages determined with respect
to animals fed with control chow receiving saline (A and B) or LPS
(C and D).
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Page 7 of 14untreated controls receiving LPS (data not shown). The
vehicle given to mice in the groups used as controls did
not significantly alter the incidence or the development
index parameters in comparison with the values
obtained for normal mice that did not receive any saline
injection (data not shown).
Celecoxib Inhibits Proadhesive Response of Melanoma
Cells to LPS-Activated Bone Marrow Stromal Cell-Derived
Factors in vitro
In the next set of experiments, monolayers from short-
term primary cultured (two-weeks) murine BMSCs were
used to analyze their contribution to the mechanism of
B16M cell adhesion under basal and LPS-induced condi-
tions. BMSCs were isolated from two representative
bones –femur and tibia–, where LPS-dependent and
-independent metastases simultaneously occurred. After
two-week culture, majority of BMSCs (97%) showed
remarkable DiI-Ac-LDL and OVA-FITC endocytosis,
and VCAM-1 expression. Of these, 48% expressed von
Willebrand antigen, suggesting their endothelial cell
phenotype. The other 52% BMSCs did not express von
Willebrand antigen but phagocytosed 1 μm-diameter
FITC-latex beads, suggesting their reticular cell pheno-
type. The 6 h-conditioned medium produced by cul-
tured BMSCs (BMSC-CM) receiving 1 ng/ml LPS
significantly (P<0 . 0 1 ) increased B16M cell adhesion to
BMSC substrate compared to the adhesion of those
receiving untreated BMSC-CM (Figure 4A). In turn,
untreated BMSC-CM also significantly (P <0 . 0 1 )
increased adhesion of B16M cells to BMSC substrate as
compared to the adhesion of basal medium-treated
B16M cells. Therefore, soluble factors from untreated
and LPS-treated BMSCs induced the adhesive phenotype
in certain B16M cells enlarging the cellular fraction able
to interact with BMSCs. More importantly, the pre-
incubation of BMSC monolayers with 10 μg/ml anti-
mouse VCAM-1 antibody for 30 min prior to adhesion
assays abolished adhesion enhancement induced by both
untreated and LPS-treated BMSC-CM, indicating that
VLA-4/VCAM-1 interaction was mediating the BMSC
attachment of B16M cells activated by BMSC-derived
factors (Figure 4A).
The role of COX-2 in the upregulation of VLA-4-stimu-
lating activity of BMSC factors on B16M cells was
addressed by exposure of B16M cells to celecoxib. Admin-
istration of 1 μg/ml celecoxib to B16M 30 min prior to
BMSC-CM completely abrogated (P < 0.01) adhesion-sti-
mulating activity of both untreated and LPS-treated
BMSC-CM (Figure 4A), indicating that BMSC factors
upregulated the ability of activated melanoma cells to
adhere to BMSCs via COX-2-dependent VLA-4 expression.
Consistent with the strong melanoma cell adhesion-
stimulating activity detected in the conditioned media
from LPS-treated BMSCs, TNFa and VEGF significantly
(P < 0.01) increased in the supernatant of LPS-activated
BMSCs as compared to untreated BMSCs (Figure 4B).
In turn, VCAM-1 expression level also significantly
increased in LPS-treated BMSCs, as evaluated by Wes-
tern blot (Figure 4C).
On the other hand, recombinant murine TNFa (10
ng/ml, 4 h) also significantly (P < 0.01) increased by
two-fold B16M cell secretion of VEGF, while addition of
celecoxib together with TNFa turned down VEGF to
basal level (Figure 4D), indicating that TNFa induced
VEGF production from B16M cells via COX-2. Interest-
ingly, the addition of 1 μg/ml anti-mouse VEGF anti-
body to B16M cells together with BMSC-CM (Figure
4A) completely abrogated adhesion-stimulating effect of
both untreated and LPS-treated BMSC-CM on B16M
cells. Conversely, rmVEGF given to B16M cells at 100
ng/ml for 4 h significantly (P< 0.01) increased B16M
cell adherence to BMSCs, and administration of 1 μg/ml
celecoxib to B16M 30 min prior to rmVEGF abolished
(P < 0.01) proadhesive effects of this cytokine. Neither
anti-mouse VEGF antibody nor celecoxib altered basal
adhesion rate of B16M cells to BMSC (Figure 4A).
Moreover, addition of 100 ng/ml rmVEGF to B16M
cells for 4 h significantly (P < 0.01) increased their adhe-
sion to immobilized VCAM-1, and 1 μg/ml celecoxib
given to B16M cells 30 min prior to rhVEGF abolished
their proadhesive effect (Figure 5A). As evaluated by
western blot, proadhesive effect of rmVEGF was accom-
panied by a significant (P < 0.05) increase of COX-2
(Figure 5B). Therefore, VEGF from both LPS-activated
BMSCs (Figure 4B) and TNFa-induced B16M (Figure
4D) induced B16M cell adhesion to BMSCs via COX-2-
dependent VLA-4 expression. Interestingly, addition of
exogenous PGE2 (given at 10 and 100 ng/ml) to B16M
cells for only 2 h significantly (P < 0.01) increased mela-
noma cell adhesion to an immobilized rhVCAM-1 sub-
strate, which further suggests that VLA-4-dependent
adhesion in VEGF-stimulated B16M cells was mediated
by COX-2-dependent PGE2 (Figure 5A)
A375 human melanoma (A375M) cells constitutively
expressed COX-2 (100% of the cell population) and
VLA-4 (50% of the cell population) [32]. Therefore,
A375M cells were similarly pre-incubated with
untreated and LPS-treated human primary cultured
BMSC-CM and their adhesion to an immobilized
rhVCAM-1 substrate was also evaluated. Consistent
with B16M cell assays, there was a statistically signifi-
cant (P< 0.01) increase in A375M cell adhesion to the
VCAM-1 substrate (Figure 5C). Celecoxib (1 μg/ml)
given 30 min prior to conditioned media of BMSCs
completely abrogated (P < 0.01) the adhesion-stimulat-
ing activity of both untreated and LPS-treated BMSC-
CM on A375M cells. Moreover, addition of 10 ng/ml
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Figure 4 (A) Effect of celecoxib and anti-VEGF on the proadhesive response of B16M cells to BMSC-CM in vitro.M u r i n eB 1 6 Mc e l l s
received 1 μg/ml celecoxib for 30 min and then incubated in the presence of basal medium, BMSC-CM, LPS-treated, BMSC-CM, rmVEGF (10 ng/
ml) or PGE2 (100ng/ml) for 4 h. In some experiments, B16M cells received 1 μg/ml murine anti-VEGF monoclonal antibody 30 min prior to BM
conditioned media. Once treatments were finished, a B16M adhesion assay to BMSCs was performed. In other experiments, anti-VCAM-1
antibody (10 μg/ml) was added to the cultures of BMSCs 30 min before adhesion assay. Differences were statistically significant cells (P < 0.01)
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melanoma cells according by ANOVA and Bonferroni’s post-hoc test. (B) Effects of LPS on TNFa and VEGF production. Supernatants were
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VEGF concentration. Statistical significance by ANOVA and Bonferroni’s posthoc test (*) p < 0.01 vs untreated BMSC. (C) Effect of LPS on VCAM-1
expression by BMSC. BMSC were treated with basal medium and LPS (1 ng/ml) for 6 h. Then, cell lysates were collected and assayed for VCAM-
1 and b-tubulin levels by western immunoblot. (D) Effect of celecoxib on TNFa-treated B16M cells. B16M cells received 1 μg/ml celecoxib 30
min prior to TNFa incubation for 4 h (10 ng/ml). Statistically significant by ANOVA and Bonferroni’s posthoc test (*) p < 0.01 vs untreated B16M
cells, (**) p < 0.01 vs TNFa-treated B16M cells. All data represent media ± SD of 3 separate experiments, each in six replicates (n = 18)
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Page 9 of 14rhVEGF to A375M cells for 4 h significantly (P <0 . 0 1 )
increased their adhesion to immobilized VCAM-1, and
1 μg/ml celecoxib given to A375M cells 30 min prior to
rhVEGF once again abolished its proadhesive effect
(Figure 5C). Thus, human A375M cells exhibited the
same functional response to endogenous VEGF shown
in B16M cells, i.e. the COX-2-dependent enlargement of
the cellular fraction able to adhere to BMSCs via
VCAM-1/VLA-4 interaction.
Tumor COX-2 Regulates VEGF-Dependent Melanoma
Proliferation in Response to BMSC-CM
Treatment with celecoxib was effective in reducing BM
metastasis volume (Figure 3B and 3D), suggesting that
COX-2 also contributed to B16M cell growth in the BM
microenvironment. As shown in Figure 6A, the condi-
tioned medium from murine untreated and LPS-treated
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Figure 6 Effect of celecoxib and anti-VEGF on the proliferation
rate of BMSC-CM-treated B16M (A) and A375M (B) cells. Murine
B16M (A) or A375M (B) cells were plated onto 96-well plates at a
density of 2,500 cells per well. Some cells received BMSC-CM, LPS-
treated BMSC-CM or 10 ng/ml rmVEGF in the presence or absence
of 1 μg/ml anti-VEGF monoclonal antibody or 1 μg/ml celecoxib.
Control melanoma cells were cultured in the presence of basal
medium (DMEM). After 48 h incubation, the number of cells was
determined by microscopic counting in 5 different fields per well
and by sulforhodamine-101-based fluorimetry as described in
Methods. Every assay was done in quadruplicate and repeated three
times. Data represent average values ± SD. Differences were
statistically significant cells (P < 0.01) with respect to (*) basal
medium- or (**) BMSC-CM- or (#) LPS-treated BMSC-CM or (##)
rmVEGF-treated melanoma cells according by ANOVA and
Bonferroni’s post-hoc test.
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Page 10 of 14BMSCs significantly (P< 0.05) stimulated proliferation of
B16M cells as compared to basal medium-treated cul-
tures. The ability of untreated and LPS-treated BMSCs
to increase B16M proliferation was completely neutra-
lized by celecoxib; however, celecoxib addition directly
to B16M cells did not affect their basal proliferation.
As above reported, BMSC-CM contained a basal con-
centration of VEGF that significantly increased (P <
0.01) upon LPS treatment, and B16M cells secreted
VEGF in response to BMSC-derived TNFa. Addition of
anti-murine VEGF antibody to B16M cells together with
BMSC-CM abolished proliferation-stimulating activity of
BMSC-CM. The addition of 10 ng/ml rmVEGF also sig-
nificantly (P < 0.01) increased B16M cell proliferation by
2-fold (P < 0.01). However, the addition of celecoxib
completely abrogated growth-promoting effect of
rmVEGF on B16M cells. These findings suggest that
VEGF generation in the bone marrow microenviroment
from both BMSCs and BMSC-activated B16M contribu-
ted to the upregulation of B16M cell growth via COX-
2-dependent mechanism.
Finally, A375M cell proliferation also significantly (P <
0.01) increased in response to untreated and LPS-treated
human BMSCs in vitro (Figure 6B). The addition of
either celecoxib or anti-human VEGF antibody to
A375M cells together with human BMSC-CM also abol-
ished proliferation-stimulating effects. Again, A375M
cells given 10 ng/ml rhVEGF also resulted in a statisti-
cally significant increase of proliferation that was com-
pletely abrogated by celecoxib.
Discussion
Although over-expression of COX-2 has been associated
to the development and progression of numerous
human malignancies, melanoma included [18-22], its
precise role along the process of cancer cell dissemina-
tion and metastasis is still poorly understood. This study
provides evidence that B16M cells metastasize in certain
bone segments of healthy mice and in the majority of
lipopolysaccharide-pretreated mice by COX-2-dependent
mechanism.
Because several bidirectional interaction mechanisms
occur between BMSCs and cancer cells, which give to
the latter a selective advantage for growing in bone [12]
and for inducing bone destruction [33], the adhesion
and proliferation of melanoma cells in response to solu-
ble factors from primary cultured BMSCs was analyzed.
Consistent with in vivo data, a COX-2-dependent
mechanism was detected, which upregulated both adhe-
sion to BMSCs and proliferation of B16M and A375M
cells in response to soluble factors released from both
untreated and LPS-treated BMSC in vitro. More impor-
tantly, VEGF –which is released to the BM microenvir-
onment by both LPS-induced BMSCs [34,35] and
TNFa-stimulated melanoma cells [36,37]– was involved
in melanoma-stimulating activities of BMSCs (Figure 7).
The mechanism was further supported by experiments
revealing COX-2 overexpression in VEGF-treated mela-
noma cells and enhanced melanoma cell adherence to
VCAM-1 induced by exogenous PGE2.
Human malignant melanoma has a propensity to
metastasize to bone, where it is exposed to high concen-
trations of growth-stimulating factors [4-6]. Melanoma
cells lodge in the BM since its earliest stage of hemato-
genous spread [1-3,38] and thereafter can produce
osteolytic metastases [39] causing severe clinical compli-
cations of the disease. The predilection of melanoma
c e l l sf o rB Mw a sp r e v i o u s l yd emonstrated by using left
cardiac ventricle-injected B16M cells [40]. Next, the pro-
metastatic support of BM-derived hematopoietic factors
[6] and its stimulation by IL-1 was suggested [41].
Moreover, in vivo endogenous IL-1 blockade with IL-1
receptor antagonist revealed that a significant number of
BM metastases from B16M are IL-1-dependent, and that
all of those developed in LPS-treated mice are IL-1-
dependent [26]. Consistent with these data, anti-
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Figure 7 Model on the contribution of TNFa, VEGF and COX-2
to melanoma metastasis-stimulating effects of bacterial
endotoxin-activated bone marrow stromal cells. TNFa
production from LPS-activated BMSCs induces VEGF production and
VCAM-1 expression from BMSCs. BMSC-derived TNFa can also
stimulate VEGF production from TNF receptor-expressing melanoma
cells via COX-2-dependent mechanism. Next, those TNF receptor-
expressing and non-TNF receptor-expressing melanoma cells that
express VEGF receptors increase proliferation and VLA-4-dependent
adhesion to BMSCs via COX-2-dependent mechanism. Therefore,
two antimetastatic intervention sites for COX-2 inhibitors may exist
in the prometastatic microenvironment generated by endotoxin-
activated bone marrow stromal cells.
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gest that COX-2 –which plays a central role in the
mechanisms of inflammation, angiogenesis and bone
remodeling [42]–, contributed to the prometastatic acti-
vation of melanoma cells in the BM microenvironment
of healthy mice and, more remarkably, of mice given
endotoxins.
Our data concerning COX-2-dependent metastases are
based on single effects of COX-2 inhibitor Celecoxib,
and doubts as to a role for off-target actions of Cele-
coxib may be raised. However, there is ample literature
suggesting that COX-2 is indeed involved in the meta-
static process [17-25,43,44]. In the present study, both
host and tumor COX-2 may be affected by in vivo Cele-
coxib treatment along BM metastasis development. It
has been reported that BMSCs adjacent to cancer cells
express COX-2 in a murine model of mammary carci-
noma [17]. Thus, the possibility that Celecoxib has
direct effects on host cell COX-2 should not be dis-
carded. However, in our study such effects might be
antimetastatic, especially if we consider that COX-2
inhibition decreases inflammatory and osteoclastic activ-
ities that characterize host cell reaction to melanoma
cell-derived cytokines [45].
On the other hand, tumor COX-2 also contributes to
cancer cell adhesion [46] and proliferation control [47].
In the present work, celecoxib abrogated BMSC-CM-
dependent upregulation of B16M cell adhesion to
BMSCs and proliferation, suggesting that BM microen-
vironment activated metastatic behavior of BM-infil-
trated B16M cells through tumor COX-2 induction.
This was consistent with current data on COX-2 expres-
sion by B16M cells and A375M included [22]. However,
our study also provides for the first time an indirect evi-
dence that host microenvironment can modulate mela-
noma COX-2 at specific compartments within a given
target organ resulting in a metastatic potential upregula-
tion. This was particularly evident in certain hemato-
poietic bony sites as for example spine, pubis, femur,
and humerus.
An additional finding was that BMSC-derived factors
enhanced attachment of B16M cells to BMSCs via
VCAM-1/VLA-4 molecular interaction mechanism.
Moreover, this proadhesive activation was COX-2-
dependent, which suggests for the first time that COX-2
is regulating murine and human melanoma cell adhe-
sion to BMSCs via VLA-4/VCAM-1 mechanism. This
was further confirmed by the enhanced adherence to
VCAM-1 of PGE2-pretreated melanoma cells. VLA-4
expression confers metastatic properties to human mela-
noma cells injected into nude mice [32] and has been
suggested as marker of poor prognosis in cancer
patients, including those affected by melanoma [48].
However, to our knowledge, this is the first evidence on
the contribution of COX-2, and more specifically PGE2,
to VLA-4-dependent melanoma cell adhesion
upregulation.
Our data also demonstrate that VEGF upregulates
B16M cell adhesion and proliferation via tumor-COX-2
mediated mechanism, suggesting that VEGF is a micro-
environmental factor promoting BM metastasis from
VEGF receptor-expressing melanoma cells. VEGF is pro-
duced by activated BMSCs and its elevation during BM
failure associated to myelofibrosis [49], leukaemia and
other neoplastic BM diseases [34] results in BM angio-
genesis [35] and mobilization of endothelial and hema-
topoietic progenitors and stem cells to the peripheral
circulation [50]. In the present study, production of
VEGF increased in LPS-treated BMSCs and neutraliza-
tion of VEGF with specific antibodies abolished the
effects of BMSC-CM on B16M cells, while B16M and
human melanoma cells given recombinant VEGF
increased their adhesion and proliferation via a cele-
coxib-inhibitable mechanism. On the other hand, several
human melanoma cell lines [34] and B16M cells [51]
also secrete biologically active VEGF. In addition, TNFa
–a major inflammatory cytokine released by BMSCs in
response to LPS–increased VEGF production from
B16M cells via COX-2 (Figure 7). In turn, VEGF
appears to induce the adhesive phenotype of B16M cells
in a similar way to activated NK cells [52]. This may
enlarge the tumor cell fraction able to interact with
BMSCs and to growth in the BM microenvironment.
Bacterial endotoxin LPS has been implicated in infec-
tious complications after cancer resection and has been
found to enhance metastasis in experimental melanoma
[26,31] and other cancer models [53,54]. Both cancer
[53] and host cell [54] response to LPS may contribute
to LPS-induced metastases. However, in our study, LPS
promoted metastasis to certain bony sites, suggesting
that prometastatic effects of LPS where mainly due to
host cell response to LPS. Not surprisingly, LPS
increased VCAM-1 expression and VEGF secretion by
BMSCs from hematopoietic bones, which promoted
melanoma cell adhesion to BMSCs via tumor COX-2-
dependent VLA-4 activation. Therefore, increased circu-
lating endotoxin may be a risk factor for bone metasta-
sis in patients with circulating melanoma cells.
However, COX-2 inhibition efficiently blocked LPS-
induced BM metastasis and decreased PGE2 production
by 4T1 cells in vitro [54].
Conclusions
In the present study we demonstrate that bone marrow
stroma cell secretion of VEGF induces melanoma cell
adhesion and growth via tumor COX-2-dependent
mechanism. This prometastatic mechanism is inducible
by bacterial endotoxins, which increase inflammatory
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Page 12 of 14cytokine production and VCAM-1 expression from bone
marrow stromal cells, and promote bone metastasis,
particularly in hematopoietic bony sites. These results
suggest that blockade of VEGF effects on metastatic
melanoma by COX-2 inhibitors represents a new thera-
peutic avenue in the prevention and treatment of bone
metastases.
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